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ABSTRACT  
 
Importance 
Mammary Analogue Secretory Carcinoma (MASC) is a newly characterized salivary gland 
carcinoma resembling secretory carcinoma of the breast. Prior to being described, MASC was 
most commonly misdiagnosed as Acinic Cell Carcinoma.  Though MASC is predominantly an 
adult neoplasm, cases have been reported in the pediatric population. Reporting and summarizing 
of known cases is imperative to understand the prognosis and clinical behavior of MASC.  
 
Objective 
(1) Report a rare case of pediatric MASC 
(2) Review and consolidate the existing literature on MASC in the pediatric population 
 
Evidence Review 
Web of Science, Medline, EMBASE, and The Cochrane Library were searched for studies that 
included pediatric cases of MASC.  Data on clinical presentation, diagnosis and management, 
and pathology were collected from all pediatric cases. 
 
Findings –  
Case Report 
14 year old with left-sided parotid mass diagnosed as MASC based on histology and 
immunohistochemistry. He was managed surgically with left superficial parotidectomy 
with selective neck dissection. 
 
Literature review 
The majority of MASC cases have been identified via retrospective reclassification of 
previously misclassified salivary gland tumors. Of all the pediatric cases (N=11) of 
MASC, the female-to-male ratio is 1:1.2 with an age range of 10-17 years old.  The most 
common clinical presentation was a slowly growing, fixed, and painless mass of the 
parotid gland, often detected incidentally on physical examination. Common pathological 
features include eosinophilic vacuolated cytoplasm within cystic, tubular, and/or 
papillary architecture.  Immunohistochemistry showed positivity for S100, 
mammaglobin, cytokeratin 19, and vimentin. The diagnosis was confirmed by the 
detection of the characteristic ETV6-NTRK6 fusion gene via fluorescent in-situ 
hybridization (FISH). Only 4 cases discussed treatment. Each of these underwent 
successful surgical resection alone with or without lymph node dissection. 
 
Conclusions and Relevance 
Since the first case of MASC in the pediatric population was described in 2011, only 12 cases, 
including this one, have been described in the literature.  With this paucity of information, much 
remains unknown regarding this new pathologic diagnosis. The collection of clinical outcomes 
data of children with MASC is needed to better understand the behavior of this malignancy as 
well as determine optimal treatment regimens. 
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1. INTRODUCTION 
 Mammary Analogue Secretory Carcinoma (MASC) of the salivary glands is a recently 
described pathologic entity of unknown incidence that resembles secretory carcinoma of the 
breast. Both tumors share the balanced translocation t(12;15) (p13;q25) forming the ETV6-
NTRK6 fusion gene which encodes a chimeric tyrosine kinase1. Prior to its description, MASC 
was most likely identified as salivary acinic cell carcinoma (AciCC), mucoepidermoid carcinoma 
(MEC), cystadenocarcinoma, or other salivary gland tumors; each shares overlapping 
histological and immunohistochemical features 2-18,23,30. With detection of the translocation by 
fluorescent in-situ hybridization (FISH), the current gold standard for diagnosis, many cases 
previously diagnosed as aforementioned salivary gland tumors have been retrospectively 
reclassified as MASC 2-18,23,30. 
 There are currently four pediatric case reports in the current literature dating back to 2011 
describing patients with MASC19-21,28. Recent case reports and studies have made efforts to 
describe the unique cytopathological and clinical characteristics as a means to accurately 
differentiate and diagnose MASC. Some key features identified include: 
• Slow growing, fixed, and painless nodule, often detected incidentally on physical 
examination1,4,5,8,15,24 
• Eosinophilic vacuolated cytoplasm within cystic, tubular, and/or papillary 
architecture4,5,22,23 
• Secretions that stain positive for periodic acid Schiff (PAS) and are diastase-resistant1,4,5,22-
26
 
• Low-grade, pale nuclei, and rare mitotic figures5,23 
• Positive staining for S-100, mammaglobin, vimentin, cytokeratin 191,4-6,13,15,22,23,25,27 
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 The purpose of this study is to report a rare case of pediatric MASC as well as to review 
and consolidate the existing literature involving this new salivary gland malignancy within the 
pediatric population.  
 
2. METHODS 
 The institutional review board (IRB) reviewed the included case report and it was 
determined that no further approval was required. Photo consent was obtained and all patient 
information was handled in a manner consistent with the Health Insurance Portability and 
Accountability Act (HIPAA). 
 We reviewed the clinical records of one child with MASC treated at our tertiary care 
pediatric hospital. Data collected included basic demographic information, clinical notes, 
pathology, laboratory and radiologic reports relevant to this study.  The patient’s medical history 
including: past medical history, surgical history, and social history were retrieved from the 
electronic medical record. 
 A literature review was performed to identify all documented cases of patients with 
MASC in the pediatric population. A medical librarian was enlisted to employ the search 
strategy included in eFigure 1 (Supplement 1).  Web of Science, Medline, EMBASE, and The 
Cochrane Library were queried and the resultant articles screened by four independent reviewers. 
Only studies that included pediatric cases of MASC were included. Clinical presentation, 
diagnosis and management, and pathology were collected for each documented case. 
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3. RESULTS  
3.1 Clinical Presentation – Case Report 
 A 14-year-old otherwise healthy male presented with a history of a left-sided facial mass 
that had been increasing in size for several months. The lesion was painless and without 
associated symptoms. Physical exam revealed a 3 cm firm, immobile mass in the patient's left 
parotid gland with no overlying skin changes. Facial movement and symmetry were intact 
bilaterally. A computed tomography (CT) scan (Figure 1) and positron emission tomography 
(PET) were obtained which demonstrated a cystic, peripherally enhancing mass centered in the 
left parotid gland measuring 2.6 cm x 2.1 cm. The left cervical lymph nodes, predominantly level 
2, were non-pathologically enlarged and mildly hypermetabolic.  
 An ultrasound-guided fine-needle aspirate (FNA) and core biopsy were performed and 
found to have cytologic features consistent with MASC. Following review by the 
multidisciplinary head and neck tumor board, the decision was made to proceed with left 
superficial parotidectomy with facial nerve (FN) dissection and left neck level II lymph node 
dissection. The surgery and post-operative course were uncomplicated. The tumor board 
recommended no further therapy and the patient is currently under routine surveillance.  
Furthermore, the patient is disease free at 14 months post-operatively. 
 
3.1.1 Assessment and Diagnosis 
 The surgical pathology of the left superficial parotidectomy and left level II neck 
dissection specimens prominently demonstrated a well demarcated but unencapsulated, yellow-
tan to red-brown, diffusely degenerative mass that has overall dimensions of 2.8 x 2.5 x 2 cm. 
The mass was focally cystic containing red-brown hemorrhagic fluid and demonstrated a 
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papillary cystic architecture.  
 Abundant granular and eosinophilic vacuolated cytoplasm within the cells, which were 
arranged in solid, tubular, and microcystic patterns with eosinophilic secretions. Perineural 
invasion (PNI) and lymphovascular invasion (LVI) were not identified. Left neck level 2 lymph 
node dissection showed no evidence of malignancy in 0 of the 17 lymph nodes (LN) identified. 
On immunohistochemistry evaluation the tumor cells were positive for S100 and mammaglobin, 
as demonstrated in Figure 2. A mucicarmine stain was negative. PAS stain highlighted some 
pink secretion within the lumen and was diastase resistant.  Fluorescence in situ hybridization 
(FISH), performed courtesy of the University of Pittsburgh Medical Center, was positive for the 
ETV6-NTRK6 fusion gene (Figure 3).  
The constellation of these findings was consistent with the diagnosis of mammary analogue 
secretory carcinoma (MASC) of the parotid gland. 
 
3.2 Review of Literature 
 The initial database query and resulted in a total of 35 articles as demonstrated in the 
prisma flow diagram in eFigure 1 (Supplement 1). Four independent reviewers screened the full 
text articles for pediatric cases of MASC and 11 articles were deemed relevant to this study. One 
paper was excluded because the pediatric case could not be distinguished from the adult cases 
reported. The 10 remaining papers included a total of 4 pediatric case reports,19-21,28 5 
retrospective reviews8,9,12,17,18 and 1 editoral letter6 of pediatric MASC, evaluating or reporting a 
total of 11 pediatric patients, which are displayed in Table 1. Based on the Oxford Center for 
Evidence-based Medicine for rating of individual studies, 5 papers were rated 5 consistent with 
“Opinion of respected authorities; case report” and the remaining 5 papers consistent with a 
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score of 4 consistent with “Case Series with or without intervention.” The majority of 
documented cases of pediatric MASC were derived from retrospective review of institutional 
archives of other salivary gland diagnoses with limited detail on the clinical presentation or 
medical and surgical management.  Of the 7 cases extracted from studies re-reviewing pathology 
archives, previous diagnoses included 3 patients 6,12,18 with AciCC, 1 with MEC, 1 with 
pleomorphic adenoma9, 1 case with MASC17 and 1 patient was not specified8.  
 
3.2.1 Clinical Presentation  
 The 11 pediatric patients ranged in age of 10-17 years with a median age of 15 years, and 
a female-to-male ratio of 1:1.2. The mean size of the tumor, reported in 10 of 11 patients, was 
2.41 cm (range 1.0-3.8 cm)6,8,9,12,18-21,28. The most common clinical presentation, in the 4 case 
reports, was a slowly enlarging, fixed, and painless mass, often detected incidentally on physical 
examination. Of 11 pediatric patients included in this analysis, 9 of the tumors were located in 
the parotid gland9,12,17,18,19-21,28, one was reported in the submandibular gland8 and one in the 
upper lip6. 
 
3.2.2 Assessment and Diagnosis 
 Work-up described in the 4 case reports included combinations of magnetic resonance 
imaging (MRI), computerized tomography (CT) and/or FNA; 2 cases utilized MRI19, 21, one 
utilized CT imaging28, and one utilized both CT imaging and MRI20. MRI findings were 
described as: well-circumscribed lesion with internal T2 hyper-intensity and intermediate T1 
signal with a dependent fluid19, mildly enhancing preauricular subcutaneous soft tissue mass20, 
and a heterogeneously enhancing tumor at the superficial parotid lobe21. CT scan findings were 
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described as a 2 x 2 cm fluid collection with rim enhancement in the anterior left parotid20. FNA 
was utilized in two cases19,20. One of which was non-diagnostic19 and the other was suggestive of 
salivary neoplasm20.  
 All 4 case reports and 6 re-review cases reported histology and immunohistochemical 
staining results, individual findings reported in Table 1. The tumors were grossly described as a 
yellow-brown to tan, well-demarcated, unencapsulated cystic mass19-21,28. Common histologic 
features comprise of a well-circumscribed mass with eosinophilic vacuolated cytoplasm within 
cystic, tubular, and/or papillary architecture, bland and low-grade nuclei, and rare mitotic 
figures. The panel of immunohistochemical stains reported varied among all studies with S100 
being the only marker tested in all patients. S100 was positive in all 11 cases. Positive staining 
for vimentin (n=4), cytokeratin 19 (n=3), and mammaglobin (n=2) has also been described in all 
cases that utilized these stains. FISH was used to detect the ETV6-NTRK3 fusion gene for final 
confirmation of MASC in 11 of the patients; all were positive apart from one case17, which was 
confirmed by histological features and immunohistochemical staining. Currently, molecular 
confirmation is considered the gold standard for the diagnosis of MASC. However, it has been 
postulated that the morphologic features together with supporting immunohistochemistry are 
sufficient for a diagnosis of MASC.10,16-18 
 
3.2.3 Treatment 
 All cases of MASC were surgically resected.  Surgical intervention and adjuvant therapy 
was discussed only in the 4 case reports19-21, 28. Two cases described superficial parotidectomy 
with FN dissection19, 20, one of which required sacrifice of the FN20, one case described a total 
parotidectomy with preservation of the FN and right selective neck dissection with exploration of 
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preauricular, level I, and level II lymph nodes 28, and one case simply reported a “tumor 
excision”21.  In all cases, post-operative radiation therapy was not deemed necessary.  
 
3.2.4 Prognosis 
 Long-term disease specific outcomes are limited due to disease incidence and reporting 
as well as the relatively new identification of MASC as a distinct pathology. One study reports a 
patient with six recurrences in a 15-year period9. No evidence of disease was reported in 5 
patients9, 12,18,21,28 , however duration of follow-up ranging from 8 months to 10 years, was only 
reported in 3 patients12,21,28.  
 
4. DISCUSSION  
 The ETV6-NTRK3 fusion gene is a result of the balanced translocation t(12;15)(p13;q25); 
the fusion gene encodes for a chimeric tyrosine kinase.1 MASC is a predominantly adult 
neoplasm, diagnosed at a median age of 45, and with a predilection for the parotid gland.4,5 
Many of the published cases of MASC are re-reviewed salivary tumors found retrospectively to 
harbor the t(12;15)(p13;q25) translocation. In the largest of these reviews, which analyze both 
adult and pediatric patients, tumors previously diagnosed as other salivary gland tumors were 
found to represent MASC4,12,23,30. Of 546 total cases of salivary gland carcinomas re-reviewed in 
these studies, 34 (6.2%) were found to be MASC. Of those that reported information on previous 
diagnosis4, 12, 30 (n=21):  15 were AciCC, 2 MEC, 2 Adenocarcinoma, 1 Cystadenocarcinoma, 
and 1 Salivary duct carcinoma.  
 The MASC diagnosis is exceedingly rare in the pediatric population with 11 cases 
reported in the literature. There is a slight male predilection with a female-to-male ratio of 1:1.2, 
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age range from 10 to 17 years old with a median of 15 years old. The typical clinical course is a 
slowly growing, painless mass most commonly of the parotid gland, detected incidentally on 
physical examination, which is consistent with what is known from the adult literature. Only 4 
studies19-21, 28 commented on initial work-up, imaging, medical and surgical management. Our 
case report of an adolescent male with a slow growing asymptomatic parotid mass, was similar 
in presentation and demographic to those in existing literature. He was also managed in a 
comparable fashion with the addition of a selective neck dissection due to the hypermetabolic 
lymph nodes seen on imaging. Though only one study reports a case of disease recurrence, and 5 
cases are reported with no evidence of disease, reporting of follow-up duration is limited to 3 
patients, leaving very little data on outcomes of MASC in the pediatric population.   
  There is insufficient data on patient outcomes to base clinical management. Optimal 
management is therefore currently unknown but given that MASC was likely previously treated 
as AciCC, managing MASC like AciCC is logical until more data is obtained on MASC. 
Additional research and long-term follow-up are necessary to determine the prognosis and 
clinical behavior of MASC in the pediatric population. Overall, MASC seems to have survival 
outcomes comparable to AciCC in the adult population.4 The reported 5-year survival for AciCC 
being 90%, but 10- and 20-year survivals are 83% and 67%, respectively.29 Data on disease 
outcomes in large cohorts of AciCC patients are well known, but complicated by the probable 
inclusion of a sub-group of patients with a diagnosis of MASC.  
 As awareness of this recently described malignancy increases and more cases are 
identified, our knowledge about this rare neoplasm should improve. Going forward, MASC 
should be included within the differential diagnosis of clinicians treating salivary gland tumors in 
adult and pediatric populations. 
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5. CONCLUSION 
 Much is still unknown about MASC, clinicians must become aware of this when 
considering salivary gland neoplasm. Reporting of clinical data, particularly clinical course, 
medical and surgical management, and long-term follow-up are greatly needed in order to guide 
clinical practice. 
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Table 1. Cases of MASC in pediatric patients reported in the literature  
 
Study 
Year 
Age/Sex Location Size 
(cm) 
Histology IHC Previous 
Diagnosis 
Outcome/ 
Follow up 
RETROSPECTIVE REVIEWS 
Jung, 
2013/ 
2015 
17 / F Parotid 1.0 • Papillary-cystic pattern 
with micropapillary 
features predominated  
(+) S-100 
 
(-) ER  
(-) PR 
 
MEC Recurred 
x 6/ 15 
years  
17 / M Parotid 1.5 • Predominant microcystic 
pattern with or without 
solid nesting 
(+) S-100 
 
(-) ER 
(-) PR 
 
PA NED, 
follow up 
not 
reported 
Ito, 2015 10 / M SMG  • Lobulated growth structure 
divided by thin fibrous 
septa with microcytic, 
tubular, solid, and 
papillary. Secretions 
present in the cystic lumens 
were colloid-like and 
eosinophilic.  
• Low Mitotic Activity 
• Necrosis was absent 
• No invasion 
(+) S-100 
(+) MGB 
Not 
Specified 
Not 
Reported 
Majewska, 
2015 
17 / M Parotid 4.0 • Macrocystic growth pattern 
• Zymogen Poor 
(+) S-100 
(+) MBG 
(+) CK7, CK8 
(+) STAT5a 
(+) Vimentin 
 
(-) p63 
(-) DOG-1 
 
AciCC NED/10 
years 
Shah*, 
2015 
16 / F Right 
Parotid 
 • cystic lesions filled with 
friable tumor with a thick 
fibrous cyst wall; tumor 
nests often focally 
extended through the cyst 
wall. Microcystic and solid 
patterns 
(+) S100 
(+) MGB 
(+)CK 
 
(-)SMA 
 
MASC Unknown 
Urano, 
2015 
14 / F Parotid 2.8 • Microcystic primary, solid 
secondary, vacuolated, 
oncocytic 
• No zymogen granules 
(+) S-100 
(+) CK19 
(+) Vimentin 
(+) LMWCK 
 
(-) DOG-1 
AciCC NED 
 
EDITORIAL LETTER 
Griffith, 
2011 
15 / M Upper 
Lip 
1.0 • PAS-D demonstrated scant 
zymogen granules 
(+) S-100 AciCC Not 
Reported 
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Study 
Year 
Age/Sex Location Size 
(cm) 
Histology IHC Previous 
Diagnosis 
Outcome/ 
Follow up 
 
CASE REPORTS 
Rastatter28 
2011 
14 / F Right 
Parotid 
3.0 • Papillary formations and 
several microscopic cystic 
spaces that are filled with 
pale eosinophilic.  
Abundant eosinophilic 
cytoplasm and prominent 
nucleoli. There were 
moderately abundant pale, 
eosinophilic, bubbly 
secretions throughout the 
tumor. 
• PAS with pale staining  
• One periparotid lymph 
node was positive for 
metastatic carcinoma.  
• Low mitotic activity 
• No significant areas of 
necrosis 
•  No PNI or LVI 
(+) S-100 Original NED, 12 
months 
post-
operativel
y 
Hwang21 
2013  
13 / M Left 
Parotid 
2.1 • Microcysts, tubular 
structures, solid nest, 
papillary architecture, with 
secretions within the cyst 
lumen Tumor cells with 
pale nuclei and centrally 
located nucleoli.  
Cytoplasm was pale 
eosinophilic to vacuolated. 
• Low mitotic activity 
• PAS, PAS-D showed 
mucin focally within the 
cells 
• No zymogen granules 
• No PNI 
(+) S-100 
(+) CK 19  
(+) Vimentin 
 
(-) CK5/6  
(-) p63 
(-) CEA,  
(-) alpha 1-
antichymotrypsin  
Original NED on 
post-
operative 
PET, 
Follow 
up: 8 
months 
Woo20 
2014  
14 / M 
setting of 
2/2 
radiation 
Left 
Parotid 
2.0 • Monotonous with granular 
and vacuolated 
amphophilic cytoplasm. 
Confluent nests and solid 
sheets. Medium-sized 
pleomorphic cells with 
abundant vacuolated 
eosinophilic cytoplasm and 
prominent nucleoli. 
Abundant extracellular 
mucin production within 
luminal structures (+) 
mucicarmine stain 
• PAS, PAS-D showed no 
evidence of true zymogen 
granule formation 
(+) S-100  
(+) Vimentin 
(+) EGFR  
 
 
(-) p63 
(-) DOG-1  
Original Not 
Reported 
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Study 
Year 
Age/Sex Location Size 
(cm) 
Histology IHC Previous 
Diagnosis 
Outcome/ 
Follow up 
• No PNI. 
Quattle- 
baum19 
2015 
15 / F Left 
Parotid 
3.0 • Within the lumen of the 
cyst were focal areas of 
neoplastic epithelial 
proliferation composed of 
uniform polygonal 
epithelial cells, some 
forming duct structures 
filled with bright 
eosinophilic seromucinous 
material and some forming 
papillary structures. 
(+) S-100 
(+) CK 19 
Original Not 
Reported 
Our Case 14 / M Left 
Parotid 
2.8 • Papillary cystic 
architecture comprised of 
cells with abundant 
granular and vacuolated 
cytoplasm and 
eccentrically located 
nuclei. Arranged in solid, 
tubular and microcystic 
patterns with somewhat 
abundant eosinophilic 
secretions 
• Focal Atypia  
• Low mitotic activity 
• (-) mucicarmine stain  
• PAS, PAS-D poorly 
highlighted some pink 
secretion within the lumen 
• No zymogen granules 
• No PNI or LVI identified 
(+) S-100 
(+) GATA-3 
(+) MGB 
 
(-) DOG-1  
(-) BRST-2 
 
 
Original NED, 
follow up 
4 months 
 
Abbreviations: BRST, breast-2.  CEA, carcinoembryonic antigen.  CK, cytokeratin.  DOG, 
discovered on GIST (Gastrointestinal Stomal Tumor). EGFR, epidermal growth factor receptor.  
ER, estrogen receptor.  LVI, lymphovascular invasion.  MGB, mammaglobin.  PAS, PAS-D, 
periodic acid-schiff diastase.  PNI, perineural invasion.  PR, progesterone receptor 
 
*tested negative for ETV6-NTRK3 fusion gene  
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Figure Legend: 
 
Figure 1. Axial computerized tomography scan. The asterisk identifies the mass in the left 
parotid gland.  
 
Figure 2. (a) Hematoxylin and Eosin, x200. (b)  s100 Immunohistochemical stain, x200. S100 
stain revealing cytoplasmic and nuclear staining. (c)  Mammaglobin Immunohistochemical stain, 
x200. Mammaglobin positivity within MASC. 
 
Figure 3. Fluorescence in situ hybridization (FISH) — positive for the ETV6-NTRK6 fusion 
gene 
 
eFigure 1 in the supplement: Prisma Flow Diagram  
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